CDK18: Cyclin Dependent Kinase 18
A PCTAIRE protein kinase involved in cell cycle regulation and DNA damage response
Gene Information Card
| Symbol | CDK18 |
|---|---|
| Full Name | Cyclin Dependent Kinase 18 |
| Gene Type | Protein coding |
| Chromosomal Location | 1q32.1 |
| NCBI Gene ID | 5129 ncbi.nlm.nih.gov/gene/5129 |
| Ensembl ID | ENSG00000117335 |
| UniProt ID | Q00536 |
| OMIM ID | 603440 |
| HGNC ID | 875 |
| Aliases | PCTAIRE, PCTK3, PCTAIRE3 |
Description
CDK18 (cyclin dependent kinase 18) is a member of the PCTAIRE subfamily of cyclin-dependent kinases. It encodes a serine/threonine protein kinase that plays a role in cell cycle progression, neuronal differentiation, and DNA damage response. The protein interacts with cyclin A or cyclin E and is involved in regulating centrosome duplication and microtubule organization. CDK18 has been implicated in cancer and neurodegenerative disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | CDK18 overexpression promotes cell proliferation and tumor growth; altered expression linked to poor prognosis | COSMIC, ClinVar |
| Colorectal cancer | Somatic mutations and copy number alterations in CDK18 contribute to tumorigenesis | COSMIC |
| Lung cancer | CDK18 amplification and overexpression observed in non-small cell lung cancer | COSMIC |
| Neurodegenerative diseases | CDK18 involved in tau phosphorylation and neuronal cell death | UniProt, OMIM |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Testis | 8.2 | Low |
| Lung | 6.1 | Low |
| Breast | 5.4 | Low |
| Colon | 4.8 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 10.3 | Overexpressed |
| A549 (lung cancer) | 8.7 | Moderate expression |
| HEK293 (embryonic kidney) | 6.5 | Baseline expression |
| SH-SY5Y (neuroblastoma) | 9.1 | High expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.101C>T (p.Thr34Met) | Missense | <0.1% | Unknown functional effect |
| c.457G>A (p.Glu153Lys) | Missense | <0.1% | Potential loss of kinase activity |
| c.832_833insA | Frameshift | <0.1% | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations predicted to truncate the kinase domain, leading to loss of catalytic activity.
Gain of Function (GOF)
Missense mutations in the activation loop may enhance kinase activity, though not well characterized.
Dominant Negative (DN)
No confirmed dominant-negative mutations reported.
View complete mutation data：
Gene Ontology (GO)
| • protein serine/threonine kinase activity | • ATP binding |
| • cyclin-dependent protein kinase activity | • cell cycle |
| • protein phosphorylation | • centrosome duplication |
| • microtubule cytoskeleton organization | • DNA damage response |
Pathways
• Cell cycle
• DNA damage response
• Neuronal differentiation
Protein Summary
CDK18 is a 473-amino acid serine/threonine kinase with a central catalytic domain and a PCTAIRE motif. It is predominantly expressed in brain and testis. The protein localizes to the cytoplasm and centrosome, and its activity is regulated by binding to cyclin A or cyclin E. CDK18 phosphorylates substrates involved in cell cycle control and cytoskeletal dynamics. Dysregulation of CDK18 is associated with cancer and neurological conditions.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CDK18 Knockout HEK293 Cell Line | EDJ-KQ4655 | Human | 5129 | Details Get a Quote |
| CDK18 Knockout HCT 116 Cell Line | EDJ-KQ28589 | Human | 5129 | Details Get a Quote |
| CDK18 Knockout HeLa Cell Line | EDJ-KQ28590 | Human | 5129 | Details Get a Quote |
| CDK18 Knockout A-549 Cell Line | EDJ-KQ62585 | Human | 5129 | Details Get a Quote |
| CDK18 Knockout HAP1 Cell Line | EDC07908 | Human | 5129 | Details Get a Quote |
